Hasil untuk "History"

G. Lukács

R. W. Mccollum

L. Degroot, E. Kaplan, Maureen Mccormick et al.

L. Strauss

D. Promislow, P. Harvey

K. Hsü, L. Montadert, D. Bernoulli et al.

P. Ginés, E. Quintero, V. Arroyo et al.

D. Carr

J. Bayart

Heather K. Love

Vincent Tam, S. Knowles, P. Cornish et al.

Background: Over a quarter of hospital prescribing errors are attributable to incomplete medication histories being obtained at the time of admission. We undertook a systematic review of studies describing the frequency, type and clinical importance of medication history errors at hospital admission. Methods: We searched MEDLINE, EMBASE and CINAHL for articles published from 1966 through April 2005 and bibliographies of papers subsequently retrieved from the search. We reviewed all published studies with quantitative results that compared prescription medication histories obtained by physicians at the time of hospital admission with comprehensive medication histories. Three reviewers independently abstracted data on methodologic features and results. Results: We identified 22 studies involving a total of 3755 patients (range 33–1053, median 104). Errors in prescription medication histories occurred in up to 67% of cases: 10%– 61% had at least 1 omission error (deletion of a drug used before admission), and 13%– 22% had at least 1 commission error (addition of a drug not used before admission); 60%– 67% had at least 1 omission or commission error. Only 5 studies (n = 545 patients) explicitly distinguished between unintentional discrepancies and intentional therapeutic changes through discussions with ordering physicians. These studies found that 27%– 54% of patients had at least 1 medication history error and that 19%– 75% of the discrepancies were unintentional. In 6 of the studies (n = 588 patients), the investigators estimated that 11%–59% of the medication history errors were clinically important. Interpretation: Medication history errors at the time of hospital admission are common and potentially clinically important. Improved physician training, accessible community pharmacy databases and closer teamwork between patients, physicians and pharmacists could reduce the frequency of these errors.

J. Raymond, J. Siefert, C. Staples et al.

M. Zuk, Andrew M Stoehr

G. Lucia, V. Springel, S. White et al.

We take advantage of the largest high-resolution simulation of cosmic structure growth ever carried out - the Millennium Simulation of the concordancecold dark matter (CDM) cosmogony - to study how the star formation histories, ages and metallicities of elliptical galaxies depend on environment and on stellar mass. We concentrate on a galaxy formation model which is tuned to fit the joint luminosity/colour/morphology distribution of low-redshift galaxies. Massive ellipticals in this model have higher metal abundances, older luminosity- weighted ages and shorter star formation time-scales, but lower assembly redshifts, than less massive systems. Within clusters the typical masses, ages and metal abundances of ellipticals are predicted to decrease, on average, with increasing distance from the cluster centre. We also quantify the effective number of progenitors of ellipticals as a function of present stellar mass, finding typical numbers below two for M∗ < 10 11 M� , rising to approximately five for the most massive systems. These findings are consistent with recent observational results that suggest 'down-sizing' or 'antihierarchical' behaviour for the star formation history of the elliptical galaxy population, despite the fact that our model includes all the standard elements of hierarchical galaxy formation and is implemented on the standard, � CDM cosmogony.

J. Wendel, R. Cronn

E. Gierlowski‐Kordesch

A. Miller‐Rushing, R. Primack, R. Bonney

M. Ratner

Syed Ameen Ahmad, Olivia Liu, Amy Feng et al.

Abstract Background There is an emerging understanding of the increased risk of stroke in patients with immune thrombocytopenic purpura (ITP) and immune thrombotic thrombocytopenic purpura (iTTP). We aimed to determine the prevalence and characteristics of acute ischemic stroke (AIS) and intracranial hemorrhage (ICH) in patients with ITP and iTTP in a systematic review and meta-analysis. Methods We used PubMed, Embase, Cochrane, Web of Science, and Scopus using text related to ITP, iTTP, stroke, AIS, and ICH from inception to 11/3/2023. Our primary outcome was to determine prevalence of AIS and/or ICH in a cohort of ITP or iTTP patients (age > 18). Our secondary outcomes were to determine stroke type associated with thrombopoietin receptor agonists (TPO-RAs) in ITP patients, as well as risk factors associated with stroke in ITP and iTTP patients. Results We included 42 studies with 118,019 patients (mean age = 50 years, 45% female). Of those, 27 studies (n = 116,334) investigated stroke in ITP patients, and 15 studies (n = 1,685) investigated stroke in iTTP patients. In all ITP patients, the prevalence of AIS and ICH was 2.1% [95% Confidence Interval (CI) 0.8-4.0%] and 1.5% (95% CI 0.9%-2.1%), respectively. ITP patients who experienced stroke as an adverse event (AE) from TPO-RAs had an AIS prevalence of 1.8% (95% CI 0.6%-3.4%) and an ICH prevalence of 2.0% (95% CI 0.2%-5.3%). Prevalence of stroke did not significantly differ between all ITP patients and those treated with TPO-RAs. iTTP patients had a prevalence of AIS and ICH of 13.9% (95% CI 10.2%-18.1%) and 3.9% (95% CI 0.2%-10.4%), respectively. Subgroup analysis revealed the prevalence of AIS and ICH was greater in iTTP patients vs. all ITP patients (p < 0.01 and p = 0.02, respectively). Meta-regression analysis revealed none of the collected variables (age, sex, history of diabetes or hypertension) were risk factors for stroke in all ITP patients, although there were high levels of data missingness. Conclusions Prevalence of different stroke types was lower in all ITP patients vs. iTTP patients. Additionally, ITP patients experienced a similar prevalence of stroke regardless of if they were specifically denoted to have been treated with TPO-RAs or not, supporting the continued use of TPO-RAs in management. Risk factors for stroke remain unclear, and future studies should continue to investigate this relationship.

Jana K. Dickter, Yuqi Zhao, Vishwas Parekh et al.

ABSTRACT We investigated the presence of viral DNA and RNA in cutaneous squamous cell carcinoma (cSCC) tumor and normal tissues from nine individuals with a history of hematopoietic stem cell transplantation (HCT). Microbiome quantification through DNA and RNA sequencing (RNA-seq) revealed the presence of 18 viruses in both tumor and normal tissues. DNA sequencing (DNA-seq) identified Torque teno virus, Saimiriine herpesvirus 1, Merkel cell polyomavirus, Human parvovirus B19, Human gammaherpesvirus-4, Human herpesvirus-6, and others. RNA-seq revealed additional viruses such as Tobamovirus, Pinus nigra virus, Orthohepadnavirus, Human papillomavirus-5, Human herpesvirus-7, Human gammaherpesvirus-4, Gammaretrovirus, and others. Notably, DNA-seq indicated that tumor samples exhibited low levels of Escherichia virus in three out of nine subjects and elevated levels of Human gammaherpesvirus-4 in one subject, while normal samples frequently contained Gammaretrovirus and occasionally Escherichia virus. A comparative analysis using both DNA- and RNA-seq captured three common viruses: Abelson murine leukemia virus, Murine type C retrovirus, and Human gammaherpesvirus-4. These findings were corroborated by an independent data set, supporting the reliability of the viral detection methods utilized. The study provides insights into the viral landscape in post-HCT patients, emphasizing the need for comprehensive viral monitoring in this vulnerable population.IMPORTANCEThis study is important because it explores the potential role of viruses in the development of cSCC in individuals who have undergone allogeneic HCT. cSCC is common in this population, particularly in those with chronic graft-versus-host disease on long-term immunosuppression. By using advanced metagenomic and metatranscriptomic next-generation sequencing, we aimed to identify viral pathogens present in tumor and adjacent normal tissue. The results could lead to targeted preventive or therapeutic interventions for these high-risk people, potentially improving their outcomes and management of cSCC.